PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications

Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry is currently used in pathology for the assessment of melanocytic neoplasms; however, knowledge of its expression patterns in soft tissue tumors is limited. PRAME immunohistochemistry (clone QR005) was assessed on whole tissue...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Virchows Archiv : an international journal of pathology Ročník 483; číslo 2; s. 145 - 156
Hlavní autoři: Cammareri, Chloé, Beltzung, Fanny, Michal, Michael, Vanhersecke, Lucile, Coindre, Jean-Michel, Velasco, Valérie, Le Loarer, François, Vergier, Béatrice, Perret, Raul
Médium: Journal Article
Jazyk:angličtina
Vydáno: Berlin/Heidelberg Springer Berlin Heidelberg 01.08.2023
Springer Nature B.V
Témata:
ISSN:0945-6317, 1432-2307, 1432-2307
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry is currently used in pathology for the assessment of melanocytic neoplasms; however, knowledge of its expression patterns in soft tissue tumors is limited. PRAME immunohistochemistry (clone QR005) was assessed on whole tissue sections of 350 soft-tissue tumors and mimics (> 50 histotypes). PRAME immunoreactivity was evaluated as follows: 0 “negative” (0% positive cells); 1+ (1–25% positive cells); 2+ (26–50% positive cells); 3+ (51–75% positive cells), and 4+ “diffuse” (> 75% positive cells). PRAME was expressed in 111 lesions (0 benign, 6 intermediate malignancy, and 105 malignant), including fibrosarcomatous dermatofibrosarcoma protuberans (2/4, 0 diffuse), NTRK -rearranged spindle cell neoplasm (2/4, 0 diffuse), atypical fibroxanthoma (1/7, 0 diffuse), Kaposi sarcoma (1/5, 0 diffuse), myxoid liposarcoma (11/11, 9 diffuse), synovial sarcoma (11/11, 6 diffuse), intimal sarcoma (7/7, 5 diffuse), biphenotypic sinonasal sarcoma (3/3, 1 diffuse), angiosarcoma (10/15, 6 diffuse), malignant peripheral nerve sheath tumor (9/12, 4 diffuse), pleomorphic rhabdomyosarcoma (2/3, 2 diffuse), alveolar rhabdomyosarcoma (2/6, 0 diffuse), embryonal rhabdomyosarcoma (7/7, 4 diffuse), undifferentiated pleomorphic sarcoma (2/12, 1 diffuse), leiomyosarcoma (2/15, 1 diffuse), clear cell sarcoma of soft tissue (1/10, 0 diffuse), low-grade fibromyxoid sarcoma (1/5, 0 diffuse), Ewing sarcoma (2/10, 1 diffuse), CIC -rearranged sarcoma (8/8, 4 diffuse), BCOR -sarcoma (2/5, 1 diffuse), melanoma (20/20, 14 diffuse), and thoracic SMARCA4-deficient undifferentiated tumor (5/5, all diffuse). All tested cases of spindle cell lipoma, dedifferentiated/pleomorphic liposarcoma, dermatofibrosarcoma protuberans, solitary fibrous tumor, inflammatory myofibroblastic tumor, myxoinflammatory fibroblastic sarcoma, nodular fasciitis, myxofibrosarcoma, epithelioid hemangioendothelioma, atypical vascular lesion, hemangioma, lymphangioma, vascular malformation, papillary endothelial hyperplasia, GIST, gastrointestinal clear-cell sarcoma, malignant melanotic nerve sheath tumor, neurofibroma, schwannoma, granular cell tumor, alveolar soft part sarcoma, epithelioid sarcoma, extraskeletal myxoid chondrosarcoma, myoepithelioma, ossifying fibromyxoid tumor, angiomatoid fibrous histiocytoma, PEComa, dermatofibroma, pleomorphic dermal sarcoma, and chordoma were negative. PRAME shows imperfect specificity in soft-tissue pathology but may serve as a diagnostic adjunct in selected differential diagnoses that show contrasting expression patterns.
AbstractList Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry is currently used in pathology for the assessment of melanocytic neoplasms; however, knowledge of its expression patterns in soft tissue tumors is limited. PRAME immunohistochemistry (clone QR005) was assessed on whole tissue sections of 350 soft-tissue tumors and mimics (> 50 histotypes). PRAME immunoreactivity was evaluated as follows: 0 "negative" (0% positive cells); 1+ (1-25% positive cells); 2+ (26-50% positive cells); 3+ (51-75% positive cells), and 4+ "diffuse" (> 75% positive cells). PRAME was expressed in 111 lesions (0 benign, 6 intermediate malignancy, and 105 malignant), including fibrosarcomatous dermatofibrosarcoma protuberans (2/4, 0 diffuse), NTRK-rearranged spindle cell neoplasm (2/4, 0 diffuse), atypical fibroxanthoma (1/7, 0 diffuse), Kaposi sarcoma (1/5, 0 diffuse), myxoid liposarcoma (11/11, 9 diffuse), synovial sarcoma (11/11, 6 diffuse), intimal sarcoma (7/7, 5 diffuse), biphenotypic sinonasal sarcoma (3/3, 1 diffuse), angiosarcoma (10/15, 6 diffuse), malignant peripheral nerve sheath tumor (9/12, 4 diffuse), pleomorphic rhabdomyosarcoma (2/3, 2 diffuse), alveolar rhabdomyosarcoma (2/6, 0 diffuse), embryonal rhabdomyosarcoma (7/7, 4 diffuse), undifferentiated pleomorphic sarcoma (2/12, 1 diffuse), leiomyosarcoma (2/15, 1 diffuse), clear cell sarcoma of soft tissue (1/10, 0 diffuse), low-grade fibromyxoid sarcoma (1/5, 0 diffuse), Ewing sarcoma (2/10, 1 diffuse), CIC-rearranged sarcoma (8/8, 4 diffuse), BCOR-sarcoma (2/5, 1 diffuse), melanoma (20/20, 14 diffuse), and thoracic SMARCA4-deficient undifferentiated tumor (5/5, all diffuse). All tested cases of spindle cell lipoma, dedifferentiated/pleomorphic liposarcoma, dermatofibrosarcoma protuberans, solitary fibrous tumor, inflammatory myofibroblastic tumor, myxoinflammatory fibroblastic sarcoma, nodular fasciitis, myxofibrosarcoma, epithelioid hemangioendothelioma, atypical vascular lesion, hemangioma, lymphangioma, vascular malformation, papillary endothelial hyperplasia, GIST, gastrointestinal clear-cell sarcoma, malignant melanotic nerve sheath tumor, neurofibroma, schwannoma, granular cell tumor, alveolar soft part sarcoma, epithelioid sarcoma, extraskeletal myxoid chondrosarcoma, myoepithelioma, ossifying fibromyxoid tumor, angiomatoid fibrous histiocytoma, PEComa, dermatofibroma, pleomorphic dermal sarcoma, and chordoma were negative. PRAME shows imperfect specificity in soft-tissue pathology but may serve as a diagnostic adjunct in selected differential diagnoses that show contrasting expression patterns.
Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry is currently used in pathology for the assessment of melanocytic neoplasms; however, knowledge of its expression patterns in soft tissue tumors is limited. PRAME immunohistochemistry (clone QR005) was assessed on whole tissue sections of 350 soft-tissue tumors and mimics (> 50 histotypes). PRAME immunoreactivity was evaluated as follows: 0 “negative” (0% positive cells); 1+ (1–25% positive cells); 2+ (26–50% positive cells); 3+ (51–75% positive cells), and 4+ “diffuse” (> 75% positive cells). PRAME was expressed in 111 lesions (0 benign, 6 intermediate malignancy, and 105 malignant), including fibrosarcomatous dermatofibrosarcoma protuberans (2/4, 0 diffuse), NTRK -rearranged spindle cell neoplasm (2/4, 0 diffuse), atypical fibroxanthoma (1/7, 0 diffuse), Kaposi sarcoma (1/5, 0 diffuse), myxoid liposarcoma (11/11, 9 diffuse), synovial sarcoma (11/11, 6 diffuse), intimal sarcoma (7/7, 5 diffuse), biphenotypic sinonasal sarcoma (3/3, 1 diffuse), angiosarcoma (10/15, 6 diffuse), malignant peripheral nerve sheath tumor (9/12, 4 diffuse), pleomorphic rhabdomyosarcoma (2/3, 2 diffuse), alveolar rhabdomyosarcoma (2/6, 0 diffuse), embryonal rhabdomyosarcoma (7/7, 4 diffuse), undifferentiated pleomorphic sarcoma (2/12, 1 diffuse), leiomyosarcoma (2/15, 1 diffuse), clear cell sarcoma of soft tissue (1/10, 0 diffuse), low-grade fibromyxoid sarcoma (1/5, 0 diffuse), Ewing sarcoma (2/10, 1 diffuse), CIC -rearranged sarcoma (8/8, 4 diffuse), BCOR -sarcoma (2/5, 1 diffuse), melanoma (20/20, 14 diffuse), and thoracic SMARCA4-deficient undifferentiated tumor (5/5, all diffuse). All tested cases of spindle cell lipoma, dedifferentiated/pleomorphic liposarcoma, dermatofibrosarcoma protuberans, solitary fibrous tumor, inflammatory myofibroblastic tumor, myxoinflammatory fibroblastic sarcoma, nodular fasciitis, myxofibrosarcoma, epithelioid hemangioendothelioma, atypical vascular lesion, hemangioma, lymphangioma, vascular malformation, papillary endothelial hyperplasia, GIST, gastrointestinal clear-cell sarcoma, malignant melanotic nerve sheath tumor, neurofibroma, schwannoma, granular cell tumor, alveolar soft part sarcoma, epithelioid sarcoma, extraskeletal myxoid chondrosarcoma, myoepithelioma, ossifying fibromyxoid tumor, angiomatoid fibrous histiocytoma, PEComa, dermatofibroma, pleomorphic dermal sarcoma, and chordoma were negative. PRAME shows imperfect specificity in soft-tissue pathology but may serve as a diagnostic adjunct in selected differential diagnoses that show contrasting expression patterns.
Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry is currently used in pathology for the assessment of melanocytic neoplasms; however, knowledge of its expression patterns in soft tissue tumors is limited. PRAME immunohistochemistry (clone QR005) was assessed on whole tissue sections of 350 soft-tissue tumors and mimics (> 50 histotypes). PRAME immunoreactivity was evaluated as follows: 0 "negative" (0% positive cells); 1+ (1-25% positive cells); 2+ (26-50% positive cells); 3+ (51-75% positive cells), and 4+ "diffuse" (> 75% positive cells). PRAME was expressed in 111 lesions (0 benign, 6 intermediate malignancy, and 105 malignant), including fibrosarcomatous dermatofibrosarcoma protuberans (2/4, 0 diffuse), NTRK-rearranged spindle cell neoplasm (2/4, 0 diffuse), atypical fibroxanthoma (1/7, 0 diffuse), Kaposi sarcoma (1/5, 0 diffuse), myxoid liposarcoma (11/11, 9 diffuse), synovial sarcoma (11/11, 6 diffuse), intimal sarcoma (7/7, 5 diffuse), biphenotypic sinonasal sarcoma (3/3, 1 diffuse), angiosarcoma (10/15, 6 diffuse), malignant peripheral nerve sheath tumor (9/12, 4 diffuse), pleomorphic rhabdomyosarcoma (2/3, 2 diffuse), alveolar rhabdomyosarcoma (2/6, 0 diffuse), embryonal rhabdomyosarcoma (7/7, 4 diffuse), undifferentiated pleomorphic sarcoma (2/12, 1 diffuse), leiomyosarcoma (2/15, 1 diffuse), clear cell sarcoma of soft tissue (1/10, 0 diffuse), low-grade fibromyxoid sarcoma (1/5, 0 diffuse), Ewing sarcoma (2/10, 1 diffuse), CIC-rearranged sarcoma (8/8, 4 diffuse), BCOR-sarcoma (2/5, 1 diffuse), melanoma (20/20, 14 diffuse), and thoracic SMARCA4-deficient undifferentiated tumor (5/5, all diffuse). All tested cases of spindle cell lipoma, dedifferentiated/pleomorphic liposarcoma, dermatofibrosarcoma protuberans, solitary fibrous tumor, inflammatory myofibroblastic tumor, myxoinflammatory fibroblastic sarcoma, nodular fasciitis, myxofibrosarcoma, epithelioid hemangioendothelioma, atypical vascular lesion, hemangioma, lymphangioma, vascular malformation, papillary endothelial hyperplasia, GIST, gastrointestinal clear-cell sarcoma, malignant melanotic nerve sheath tumor, neurofibroma, schwannoma, granular cell tumor, alveolar soft part sarcoma, epithelioid sarcoma, extraskeletal myxoid chondrosarcoma, myoepithelioma, ossifying fibromyxoid tumor, angiomatoid fibrous histiocytoma, PEComa, dermatofibroma, pleomorphic dermal sarcoma, and chordoma were negative. PRAME shows imperfect specificity in soft-tissue pathology but may serve as a diagnostic adjunct in selected differential diagnoses that show contrasting expression patterns.Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry is currently used in pathology for the assessment of melanocytic neoplasms; however, knowledge of its expression patterns in soft tissue tumors is limited. PRAME immunohistochemistry (clone QR005) was assessed on whole tissue sections of 350 soft-tissue tumors and mimics (> 50 histotypes). PRAME immunoreactivity was evaluated as follows: 0 "negative" (0% positive cells); 1+ (1-25% positive cells); 2+ (26-50% positive cells); 3+ (51-75% positive cells), and 4+ "diffuse" (> 75% positive cells). PRAME was expressed in 111 lesions (0 benign, 6 intermediate malignancy, and 105 malignant), including fibrosarcomatous dermatofibrosarcoma protuberans (2/4, 0 diffuse), NTRK-rearranged spindle cell neoplasm (2/4, 0 diffuse), atypical fibroxanthoma (1/7, 0 diffuse), Kaposi sarcoma (1/5, 0 diffuse), myxoid liposarcoma (11/11, 9 diffuse), synovial sarcoma (11/11, 6 diffuse), intimal sarcoma (7/7, 5 diffuse), biphenotypic sinonasal sarcoma (3/3, 1 diffuse), angiosarcoma (10/15, 6 diffuse), malignant peripheral nerve sheath tumor (9/12, 4 diffuse), pleomorphic rhabdomyosarcoma (2/3, 2 diffuse), alveolar rhabdomyosarcoma (2/6, 0 diffuse), embryonal rhabdomyosarcoma (7/7, 4 diffuse), undifferentiated pleomorphic sarcoma (2/12, 1 diffuse), leiomyosarcoma (2/15, 1 diffuse), clear cell sarcoma of soft tissue (1/10, 0 diffuse), low-grade fibromyxoid sarcoma (1/5, 0 diffuse), Ewing sarcoma (2/10, 1 diffuse), CIC-rearranged sarcoma (8/8, 4 diffuse), BCOR-sarcoma (2/5, 1 diffuse), melanoma (20/20, 14 diffuse), and thoracic SMARCA4-deficient undifferentiated tumor (5/5, all diffuse). All tested cases of spindle cell lipoma, dedifferentiated/pleomorphic liposarcoma, dermatofibrosarcoma protuberans, solitary fibrous tumor, inflammatory myofibroblastic tumor, myxoinflammatory fibroblastic sarcoma, nodular fasciitis, myxofibrosarcoma, epithelioid hemangioendothelioma, atypical vascular lesion, hemangioma, lymphangioma, vascular malformation, papillary endothelial hyperplasia, GIST, gastrointestinal clear-cell sarcoma, malignant melanotic nerve sheath tumor, neurofibroma, schwannoma, granular cell tumor, alveolar soft part sarcoma, epithelioid sarcoma, extraskeletal myxoid chondrosarcoma, myoepithelioma, ossifying fibromyxoid tumor, angiomatoid fibrous histiocytoma, PEComa, dermatofibroma, pleomorphic dermal sarcoma, and chordoma were negative. PRAME shows imperfect specificity in soft-tissue pathology but may serve as a diagnostic adjunct in selected differential diagnoses that show contrasting expression patterns.
Author Beltzung, Fanny
Vanhersecke, Lucile
Coindre, Jean-Michel
Le Loarer, François
Velasco, Valérie
Vergier, Béatrice
Perret, Raul
Cammareri, Chloé
Michal, Michael
Author_xml – sequence: 1
  givenname: Chloé
  surname: Cammareri
  fullname: Cammareri, Chloé
  organization: University of Bordeaux, Department of Biopathology, Institut Bergonié
– sequence: 2
  givenname: Fanny
  surname: Beltzung
  fullname: Beltzung, Fanny
  organization: Department of Pathology, Bordeaux University Hospital
– sequence: 3
  givenname: Michael
  surname: Michal
  fullname: Michal, Michael
  organization: Department of Pathology, Faculty of Medicine in Plzen, Charles University, Bioptical Laboratory Ltd
– sequence: 4
  givenname: Lucile
  surname: Vanhersecke
  fullname: Vanhersecke, Lucile
  organization: Department of Biopathology, Institut Bergonié
– sequence: 5
  givenname: Jean-Michel
  surname: Coindre
  fullname: Coindre, Jean-Michel
  organization: University of Bordeaux, Department of Biopathology, Institut Bergonié
– sequence: 6
  givenname: Valérie
  surname: Velasco
  fullname: Velasco, Valérie
  organization: Department of Biopathology, Institut Bergonié
– sequence: 7
  givenname: François
  surname: Le Loarer
  fullname: Le Loarer, François
  organization: University of Bordeaux, Department of Biopathology, Institut Bergonié, INSERM U1218, ACTION, Institut Bergonié
– sequence: 8
  givenname: Béatrice
  surname: Vergier
  fullname: Vergier, Béatrice
  organization: University of Bordeaux, Department of Pathology, Bordeaux University Hospital
– sequence: 9
  givenname: Raul
  orcidid: 0000-0003-2698-0249
  surname: Perret
  fullname: Perret, Raul
  email: r.perret@bordeaux.unicancer.fr
  organization: Department of Biopathology, Institut Bergonié, INSERM U1218, ACTION, Institut Bergonié
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37477762$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1u1DAUhS1URKeFF2CBLLFhE7ixHTthV1WlRSoCIVhHHseZcZXYwdde5Il4TTydAlIXXVh34e_cn3POyIkP3hLyuob3NYD6gACCtRUwXgGXICv5jGxqwVnFOKgTsoFONJXktTolZ4h3AKxua_mCnHIllFKSbcjvb98vvlxRN8_Zh73DFMzezqXGlTpPMYyJJoeYLU15DhGp9gOd3ewMfqSaYsrDSsNIeQPUaLRI9263n8pLzu-oS1iaLzaO1iSKizVudMallW5zoktI1ienp2mlGe2YJzo4vfMBkzNUL8vkjE4ueHxJno96QvvqoZ6Tn5-uflzeVLdfrz9fXtxWhqsmVa3hDLZCG2EakBKE0eVSYRvGFDDQrdyOdpStVqx86cF0o-aiU7o2jZDdwM_Ju2PfJYZf2WLqixnGTpP2NmTsWStqKM0aWdC3j9C7kKMv2x2oFmrWtU2h3jxQeTvboV-im3Vc-78RFIAdARMDYrTjP6SG_pBzf8y5Lzn39zn3h9ntI1Hx9N6pFLWbnpbyoxTLHL-z8f_aT6j-AOSpvwg
CitedBy_id crossref_primary_10_1111_cup_14824
crossref_primary_10_1038_s41388_025_03547_1
crossref_primary_10_1016_j_modpat_2025_100879
crossref_primary_10_1093_ajcp_aqaf084
crossref_primary_10_3390_ijms242115881
crossref_primary_10_3390_ijms25031582
crossref_primary_10_3390_ijtm3030024
crossref_primary_10_1016_j_semdp_2025_150937
crossref_primary_10_3390_diagnostics13243636
crossref_primary_10_1038_s41598_024_74556_5
crossref_primary_10_1016_j_path_2025_05_002
crossref_primary_10_1111_cup_14806
crossref_primary_10_1177_10668969241271902
crossref_primary_10_1016_j_anndiagpath_2025_152497
Cites_doi 10.1002/gcc.22254
10.1002/gcc.20827
10.1111/his.14312
10.1111/cup.14000
10.1001/jamaophthalmol.2017.0729
10.1016/j.jtho.2016.08.1206
10.1182/blood-2008-07-170282
10.1111/cup.13876
10.1111/his.14814
10.3389/fonc.2021.675296
10.1097/pas.0000000000001944
10.3390/cancers12123612
10.1097/pas.0000000000001878
10.1177/10668969211012085
10.1016/j.path.2021.01.001
10.1097/PAS.0000000000001645
10.1016/j.humpath.2016.12.006
10.1097/dad.0000000000002208
10.1097/pas.0000000000001393
10.1016/j.cell.2005.07.003
10.3390/cancers13153864
10.1111/his.14797
10.1097/dad.0000000000001885
10.1111/cup.13812
10.1111/cup.14163
10.1002/cjp2.16
10.1016/s1074-7613(00)80426-4
10.1136/esmoopen-2016-000068
10.1093/jnen/nlaa125
ContentType Journal Article
Copyright The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Copyright_xml – notice: The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7T5
7T7
7TM
7TO
7U7
7U9
7X7
7XB
88A
88E
8AO
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
KB0
LK8
M0S
M1P
M7P
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1007/s00428-023-03606-6
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Toxicology Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Database
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
ProQuest SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Biological Sciences
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
Biological Science Database
ProQuest Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
Toxicology Abstracts
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
ProQuest Medical Library
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
ProQuest Central Student

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1432-2307
EndPage 156
ExternalDocumentID 37477762
10_1007_s00428_023_03606_6
Genre Journal Article
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.55
.86
.GJ
.VR
04C
06C
06D
0R~
0VY
1N0
2.D
203
28-
29Q
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
3O-
3V.
4.4
406
408
409
40D
40E
53G
5QI
5RE
5VS
67Z
6NX
78A
7RV
7X7
88A
88E
8AO
8FE
8FH
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABOCM
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACUDM
ACZOJ
ADBBV
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEUYN
AEVLU
AEXYK
AFBBN
AFEXP
AFFNX
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBNVY
BBWZM
BDATZ
BENPR
BGNMA
BHPHI
BKEYQ
BMSDO
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBLON
EBS
EIHBH
EIOEI
EJD
EMOBN
EN4
ESBYG
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
H13
HCIFZ
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAS
LK8
LLZTM
M0L
M1P
M4Y
M7P
MA-
N2Q
N9A
NAPCQ
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R89
R9I
RHV
RIG
RNI
RNS
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
WOW
X7M
YLTOR
Z45
Z7U
Z81
Z82
Z87
Z8O
Z8U
Z8V
Z91
ZGI
ZMTXR
ZOVNA
~EX
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ABRTQ
ACSTC
ADHKG
AEZWR
AFDZB
AFFHD
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7T7
7TM
7TO
7U7
7U9
7XB
8FD
8FK
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
P64
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
ID FETCH-LOGICAL-c375t-8c320b4ac4c506604ca4774e5227020a86bfef68a724caadc9fa3497a1c5469d3
IEDL.DBID RSV
ISICitedReferencesCount 16
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001034307500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0945-6317
1432-2307
IngestDate Fri Sep 05 12:24:40 EDT 2025
Wed Nov 05 02:25:57 EST 2025
Thu Apr 03 07:10:12 EDT 2025
Tue Nov 18 21:49:38 EST 2025
Sat Nov 29 04:14:04 EST 2025
Fri Feb 21 02:43:25 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Immunohistochemistry
Sarcoma
Immunotherapy
Melanoma
PRAME
Soft tissue
Differential diagnosis
Language English
License 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c375t-8c320b4ac4c506604ca4774e5227020a86bfef68a724caadc9fa3497a1c5469d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-2698-0249
PMID 37477762
PQID 2848012985
PQPubID 54092
PageCount 12
ParticipantIDs proquest_miscellaneous_2841022756
proquest_journals_2848012985
pubmed_primary_37477762
crossref_primary_10_1007_s00428_023_03606_6
crossref_citationtrail_10_1007_s00428_023_03606_6
springer_journals_10_1007_s00428_023_03606_6
PublicationCentury 2000
PublicationDate 20230800
2023-08-00
2023-Aug
20230801
PublicationDateYYYYMMDD 2023-08-01
PublicationDate_xml – month: 8
  year: 2023
  text: 20230800
PublicationDecade 2020
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationSubtitle European Journal of Pathology
PublicationTitle Virchows Archiv : an international journal of pathology
PublicationTitleAbbrev Virchows Arch
PublicationTitleAlternate Virchows Arch
PublicationYear 2023
Publisher Springer Berlin Heidelberg
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
References Albertsmeier, Altendorf-Hofmann, Lindner (CR24) 2020; 12
Santandrea, Valli, Zanetti (CR12) 2022; 46
Gradecki, Valdes-Rodriguez, Wick, Gru (CR7) 2021; 78
Raghavan, Wang, Toland (CR14) 2020; 47
Iura, Kohashi, Hotokebuchi (CR30) 2015; 1
Gradecki, Slingluff, Gru (CR11) 2021; 48
Lezcano, Müller, Frosina (CR27) 2021; 29
Googe, Flanigan, Miedema (CR16) 2021; 43
Gerami, Benton, Zhao (CR19) 2022; 44
Pujol, De Pas, Rittmeyer (CR5) 2016; 11
Wang, Zehir, Sadowska (CR28) 2015; 54
Agaimy, Stoehr, Hornung (CR20) 2021; 45
Lezcano, Jungbluth, Busam (CR10) 2021; 14
Iura, Maekawa, Kohashi (CR26) 2017; 61
Chen, Zhang, Qiu, Ke, Chen, Chen (CR15) 2023; 82
Epping, Wang, Edel, Carlée, Hernandez, Bernards (CR2) 2005; 122
Kaczorowski, Chłopek, Kruczak, Ryś, Lasota, Miettinen (CR13) 2022; 46
Lezcano, Pulitzer, Moy, Hollmann, Jungbluth, Busam (CR9) 2020; 44
Hrycaj, Szczepanski, Zhao (CR25) 2022; 81
Ferrara, Argenziano (CR17) 2021; 11
Gutzmer, Rivoltini, Levchenko (CR4) 2016; 1
(CR23) 2020
Guo, Zhang, Chang, Singer, Maki, Antonescu (CR29) 2011; 50
Alomari, Tharp, Umphress, Kowal (CR8) 2021; 48
Ikeda, Lethé, Lehmann (CR1) 1997; 6
Oehler, Guthrie, Cummings (CR3) 2009; 114
Cesinaro, Piana, Paganelli, Pedroni, Santandrea, Maiorana (CR22) 2022; 49
Cadwell, Yuksek, Hirbe (CR21) 2021; 80
Gezgin, Luk, Cao (CR6) 2017; 135
Gassenmaier, Hahn, Metzler (CR18) 2021; 13
AK Alomari (3606_CR8) 2021; 48
AM Cesinaro (3606_CR22) 2022; 49
CR Cadwell (3606_CR21) 2021; 80
G Santandrea (3606_CR12) 2022; 46
YP Chen (3606_CR15) 2023; 82
C Lezcano (3606_CR27) 2021; 29
G Gezgin (3606_CR6) 2017; 135
A Agaimy (3606_CR20) 2021; 45
M Gassenmaier (3606_CR18) 2021; 13
L Wang (3606_CR28) 2015; 54
C Lezcano (3606_CR9) 2020; 44
SE Gradecki (3606_CR11) 2021; 48
K Iura (3606_CR30) 2015; 1
SE Gradecki (3606_CR7) 2021; 78
H Ikeda (3606_CR1) 1997; 6
PB Googe (3606_CR16) 2021; 43
VG Oehler (3606_CR3) 2009; 114
P Gerami (3606_CR19) 2022; 44
G Ferrara (3606_CR17) 2021; 11
MT Epping (3606_CR2) 2005; 122
R Gutzmer (3606_CR4) 2016; 1
K Iura (3606_CR26) 2017; 61
C Lezcano (3606_CR10) 2021; 14
WHO Classification of Tumours editorial board (3606_CR23) 2020
T Guo (3606_CR29) 2011; 50
M Kaczorowski (3606_CR13) 2022; 46
SS Raghavan (3606_CR14) 2020; 47
M Albertsmeier (3606_CR24) 2020; 12
JL Pujol (3606_CR5) 2016; 11
SM Hrycaj (3606_CR25) 2022; 81
References_xml – volume: 54
  start-page: 463
  year: 2015
  end-page: 471
  ident: CR28
  article-title: Consistent copy number changes and recurrent PRKAR1A mutations distinguish melanotic schwannomas from melanomas: SNP-array and next generation sequencing analysis
  publication-title: Genes Chromosom Cancer
  doi: 10.1002/gcc.22254
– volume: 50
  start-page: 25
  year: 2011
  end-page: 33
  ident: CR29
  article-title: Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions
  publication-title: Genes Chromosom Cancer
  doi: 10.1002/gcc.20827
– volume: 78
  start-page: 1000
  year: 2021
  end-page: 1008
  ident: CR7
  article-title: PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna
  publication-title: Histopathology
  doi: 10.1111/his.14312
– volume: 48
  start-page: 1115
  year: 2021
  end-page: 1123
  ident: CR8
  article-title: The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors
  publication-title: J Cutan Pathol
  doi: 10.1111/cup.14000
– volume: 135
  start-page: 541
  year: 2017
  end-page: 549
  ident: CR6
  article-title: PRAME as a potential target for immunotherapy in metastatic uveal melanoma
  publication-title: JAMA Ophthalmol
  doi: 10.1001/jamaophthalmol.2017.0729
– volume: 11
  start-page: 2208
  year: 2016
  end-page: 2217
  ident: CR5
  article-title: Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase I dose escalation study
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2016.08.1206
– volume: 114
  start-page: 3299
  year: 2009
  end-page: 3308
  ident: CR3
  article-title: The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells
  publication-title: Blood
  doi: 10.1182/blood-2008-07-170282
– volume: 48
  start-page: 479
  year: 2021
  end-page: 485
  ident: CR11
  article-title: PRAME expression in 155 cases of metastatic melanoma
  publication-title: J Cutan Pathol
  doi: 10.1111/cup.13876
– volume: 82
  start-page: 285
  year: 2023
  end-page: 295
  ident: CR15
  article-title: PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics
  publication-title: Histopathology
  doi: 10.1111/his.14814
– volume: 11
  start-page: 675296
  year: 2021
  ident: CR17
  article-title: The WHO 2018 classification of cutaneous melanocytic neoplasms: suggestions from routine practice
  publication-title: Front Oncol
  doi: 10.3389/fonc.2021.675296
– volume: 46
  start-page: 1467
  year: 2022
  end-page: 1476
  ident: CR13
  article-title: PRAME expression in cancer. a systematic immunohistochemical study of >5800 epithelial and nonepithelial tumors
  publication-title: Am J Surg Pathol
  doi: 10.1097/pas.0000000000001944
– volume: 12
  start-page: 3612
  year: 2020
  ident: CR24
  article-title: Cancer testis antigens and immunotherapy: expression of PRAME is associated with prognosis in soft tissue sarcoma
  publication-title: Cancers
  doi: 10.3390/cancers12123612
– volume: 46
  start-page: 579
  year: 2022
  end-page: 590
  ident: CR12
  article-title: Comparative analysis of PRAME expression in 127 acral and nail melanocytic lesions
  publication-title: Am J Surg Pathol
  doi: 10.1097/pas.0000000000001878
– volume: 29
  start-page: 826
  year: 2021
  end-page: 835
  ident: CR27
  article-title: Immunohistochemical detection of cancer-testis antigen PRAME
  publication-title: Int J Surg Pathol
  doi: 10.1177/10668969211012085
– volume: 14
  start-page: 165
  year: 2021
  end-page: 175
  ident: CR10
  article-title: PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions
  publication-title: Surg Pathol Clin
  doi: 10.1016/j.path.2021.01.001
– volume: 45
  start-page: 240
  year: 2021
  end-page: 254
  ident: CR20
  article-title: Dedifferentiated and undifferentiated melanomas: report of 35 new cases with literature review and proposal of diagnostic criteria
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0000000000001645
– year: 2020
  ident: CR23
  publication-title: Soft tissue and bone tumours 5th edn
– volume: 61
  start-page: 130
  year: 2017
  end-page: 139
  ident: CR26
  article-title: Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2016.12.006
– volume: 44
  start-page: 575
  year: 2022
  end-page: 580
  ident: CR19
  article-title: PRAME expression correlates with genomic aberration and malignant diagnosis of spitzoid melanocytic neoplasms
  publication-title: Am J Dermatopathol
  doi: 10.1097/dad.0000000000002208
– volume: 44
  start-page: 503
  year: 2020
  end-page: 508
  ident: CR9
  article-title: Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma
  publication-title: Am J Surg Pathol
  doi: 10.1097/pas.0000000000001393
– volume: 122
  start-page: 835
  year: 2005
  end-page: 847
  ident: CR2
  article-title: The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling
  publication-title: Cell
  doi: 10.1016/j.cell.2005.07.003
– volume: 13
  start-page: 3864
  year: 2021
  ident: CR18
  article-title: Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas
  publication-title: Cancers
  doi: 10.3390/cancers13153864
– volume: 81
  start-page: 818
  year: 2022
  end-page: 825
  ident: CR25
  article-title: PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumor, and other cutaneous sarcomatoid neoplasms: a comparative analysis
  publication-title: Histopathology
  doi: 10.1111/his.14797
– volume: 43
  start-page: 794
  year: 2021
  end-page: 800
  ident: CR16
  article-title: Preferentially expressed antigen in melanoma immunostaining in a series of melanocytic neoplasms
  publication-title: Am J Dermatopathol
  doi: 10.1097/dad.0000000000001885
– volume: 47
  start-page: 1226
  year: 2020
  end-page: 1228
  ident: CR14
  article-title: Diffuse PRAME expression is highly specific for malignant melanoma in the distinction from clear cell sarcoma
  publication-title: J Cutan Pathol
  doi: 10.1111/cup.13812
– volume: 49
  start-page: 338
  year: 2022
  end-page: 342
  ident: CR22
  article-title: PRAME expression in cellular neurothekeoma: a study of 11 cases
  publication-title: J Cutan Pathol
  doi: 10.1111/cup.14163
– volume: 1
  start-page: 144
  year: 2015
  end-page: 159
  ident: CR30
  article-title: Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma
  publication-title: J Pathol Clin Res
  doi: 10.1002/cjp2.16
– volume: 6
  start-page: 199
  year: 1997
  end-page: 208
  ident: CR1
  article-title: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor
  publication-title: Immunity
  doi: 10.1016/s1074-7613(00)80426-4
– volume: 1
  start-page: e000068
  year: 2016
  ident: CR4
  article-title: Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
  publication-title: ESMO Open
  doi: 10.1136/esmoopen-2016-000068
– volume: 80
  start-page: 384
  year: 2021
  end-page: 386
  ident: CR21
  article-title: Preferentially expressed antigen in melanoma (PRAME) expression in malignant, but not benign, peripheral nerve sheath tumors
  publication-title: J Neuropathol Exp Neurol
  doi: 10.1093/jnen/nlaa125
– volume: 46
  start-page: 579
  year: 2022
  ident: 3606_CR12
  publication-title: Am J Surg Pathol
  doi: 10.1097/pas.0000000000001878
– volume: 78
  start-page: 1000
  year: 2021
  ident: 3606_CR7
  publication-title: Histopathology
  doi: 10.1111/his.14312
– volume-title: Soft tissue and bone tumours 5th edn
  year: 2020
  ident: 3606_CR23
– volume: 46
  start-page: 1467
  year: 2022
  ident: 3606_CR13
  publication-title: Am J Surg Pathol
  doi: 10.1097/pas.0000000000001944
– volume: 50
  start-page: 25
  year: 2011
  ident: 3606_CR29
  publication-title: Genes Chromosom Cancer
  doi: 10.1002/gcc.20827
– volume: 11
  start-page: 2208
  year: 2016
  ident: 3606_CR5
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2016.08.1206
– volume: 135
  start-page: 541
  year: 2017
  ident: 3606_CR6
  publication-title: JAMA Ophthalmol
  doi: 10.1001/jamaophthalmol.2017.0729
– volume: 61
  start-page: 130
  year: 2017
  ident: 3606_CR26
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2016.12.006
– volume: 11
  start-page: 675296
  year: 2021
  ident: 3606_CR17
  publication-title: Front Oncol
  doi: 10.3389/fonc.2021.675296
– volume: 13
  start-page: 3864
  year: 2021
  ident: 3606_CR18
  publication-title: Cancers
  doi: 10.3390/cancers13153864
– volume: 80
  start-page: 384
  year: 2021
  ident: 3606_CR21
  publication-title: J Neuropathol Exp Neurol
  doi: 10.1093/jnen/nlaa125
– volume: 44
  start-page: 575
  year: 2022
  ident: 3606_CR19
  publication-title: Am J Dermatopathol
  doi: 10.1097/dad.0000000000002208
– volume: 48
  start-page: 479
  year: 2021
  ident: 3606_CR11
  publication-title: J Cutan Pathol
  doi: 10.1111/cup.13876
– volume: 1
  start-page: 144
  year: 2015
  ident: 3606_CR30
  publication-title: J Pathol Clin Res
  doi: 10.1002/cjp2.16
– volume: 1
  start-page: e000068
  year: 2016
  ident: 3606_CR4
  publication-title: ESMO Open
  doi: 10.1136/esmoopen-2016-000068
– volume: 14
  start-page: 165
  year: 2021
  ident: 3606_CR10
  publication-title: Surg Pathol Clin
  doi: 10.1016/j.path.2021.01.001
– volume: 48
  start-page: 1115
  year: 2021
  ident: 3606_CR8
  publication-title: J Cutan Pathol
  doi: 10.1111/cup.14000
– volume: 43
  start-page: 794
  year: 2021
  ident: 3606_CR16
  publication-title: Am J Dermatopathol
  doi: 10.1097/dad.0000000000001885
– volume: 47
  start-page: 1226
  year: 2020
  ident: 3606_CR14
  publication-title: J Cutan Pathol
  doi: 10.1111/cup.13812
– volume: 82
  start-page: 285
  year: 2023
  ident: 3606_CR15
  publication-title: Histopathology
  doi: 10.1111/his.14814
– volume: 44
  start-page: 503
  year: 2020
  ident: 3606_CR9
  publication-title: Am J Surg Pathol
  doi: 10.1097/pas.0000000000001393
– volume: 29
  start-page: 826
  year: 2021
  ident: 3606_CR27
  publication-title: Int J Surg Pathol
  doi: 10.1177/10668969211012085
– volume: 81
  start-page: 818
  year: 2022
  ident: 3606_CR25
  publication-title: Histopathology
  doi: 10.1111/his.14797
– volume: 45
  start-page: 240
  year: 2021
  ident: 3606_CR20
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0000000000001645
– volume: 49
  start-page: 338
  year: 2022
  ident: 3606_CR22
  publication-title: J Cutan Pathol
  doi: 10.1111/cup.14163
– volume: 12
  start-page: 3612
  year: 2020
  ident: 3606_CR24
  publication-title: Cancers
  doi: 10.3390/cancers12123612
– volume: 6
  start-page: 199
  year: 1997
  ident: 3606_CR1
  publication-title: Immunity
  doi: 10.1016/s1074-7613(00)80426-4
– volume: 122
  start-page: 835
  year: 2005
  ident: 3606_CR2
  publication-title: Cell
  doi: 10.1016/j.cell.2005.07.003
– volume: 114
  start-page: 3299
  year: 2009
  ident: 3606_CR3
  publication-title: Blood
  doi: 10.1182/blood-2008-07-170282
– volume: 54
  start-page: 463
  year: 2015
  ident: 3606_CR28
  publication-title: Genes Chromosom Cancer
  doi: 10.1002/gcc.22254
SSID ssj0021816
Score 2.464075
Snippet Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry is currently used in pathology for the assessment of melanocytic neoplasms; however,...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 145
SubjectTerms Adult
Alveoli
Antigens
Antigens, Neoplasm
Biomarkers, Tumor - metabolism
Chondrosarcoma
Dermatofibrosarcoma protuberans
Diagnosis, Differential
Diagnostic software
DNA Helicases
Ewing's sarcoma
Ewings sarcoma
Extraskeletal myxoid chondrosarcoma
Fasciitis
Fibrosarcoma - diagnosis
Head & neck cancer
Hemangioma
Histiocytoma
Humans
Hyperplasia
Immunohistochemistry
Inflammation
Lesions
Lipoma
Liposarcoma
Lymphangioma
Malignancy
Medical diagnosis
Medicine
Medicine & Public Health
Melanoma
Melanoma - pathology
Neoplasms
Nuclear Proteins
Original Article
Pathology
Peripheral nerves
Rhabdomyosarcoma
Sarcoma
Sarcoma - diagnosis
Sarcoma - pathology
Sarcoma, Ewing - diagnosis
Schwann cells
Sheaths
Skin Neoplasms - pathology
Soft Tissue Neoplasms - diagnosis
Soft Tissue Neoplasms - pathology
Soft tissues
Synovial sarcoma
Thorax
Tissues
Transcription Factors
Tumors
SummonAdditionalLinks – databaseName: Biological Science Database
  dbid: M7P
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagIMSFd2GhoEHiBhbJ2k5iLqhCrTjQaoUA9RbZji1FyibLJqnUX8TfZOx1UlBFLxwjJ46TGc_M53kR8sZabWQhNbVCaMpTnlKpdEYL7VKFBr1QoVzTjy_56WlxdiZX8cCtj2GVk0wMgrrqjD8jf49i1AtTWYiPm5_Ud43y3tXYQuMmueWrJLAQureaARdqr-CrlFzQDBVlTJoJqXMBLFDUWBRlOKLq7G_FdMXavOIpDQro-P7_Lv0BuRdNTzjc8cpDcsO2j8idk-hcf0x-rb4enhxB7TNGulCH2Ezd4KBuoUeBDUOgEwzjutv2oNoK1vW6Nv0HUBAq1ULngIkEDGrHHnwx5MbDf_wiqIceJ9_YrY8gAZ_i6cOUEAWAHgfYdIMPXFJNcwFjb93YQLULA8Tlwp9-9ifk-_HRt0-faezjQA3LxUALw5aJ5spwI9DCSbhRHK1Oi6ZfjtaqKjLtrMsKlS9xSFVGOsW4zFVqBKL3iu2TvbZr7TMCUidVYjLrGP5U7-LjGi8rxGFMOVm4BUknIpYmFjn3vTaaci7PHAhfIuHLQPgyW5C38zObXYmPa-8-mIhcxu3el5cUXpDX8zBSyHtfVGu7Mdzj0XUucIqnO56aX8cQ1OWolhbk3cRkl5P_ey3Pr1_LC3J3GRjchysekL1hO9qX5LY5R17Zvgpb5TcIaBrX
  priority: 102
  providerName: ProQuest
Title PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications
URI https://link.springer.com/article/10.1007/s00428-023-03606-6
https://www.ncbi.nlm.nih.gov/pubmed/37477762
https://www.proquest.com/docview/2848012985
https://www.proquest.com/docview/2841022756
Volume 483
WOSCitedRecordID wos001034307500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAVX
  databaseName: SpringerLink
  customDbUrl:
  eissn: 1432-2307
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0021816
  issn: 0945-6317
  databaseCode: RSV
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA_enYgvfp-unssIvmmg3SZt4tspe_jgLcuqy76VJE2h0G2XbSvcX3T_ppNsW5VTQV8KJWk6MJP8fsN8hJDX1mojhdTUcq4pC1lIpdIxFToPFRJ6rny7pvWnZLEQm41c9kVhzZDtPoQk_Uk9Frt5ek8RYyieuugHx0fkBOFOuO24-rwe3SzELB-hlIzTGOGxL5X5_Rq_wtENjnkjPuph5-L-_wn8gNzraSacH-ziIbllq0fkzmUfSH9Mrper88s5FK46pPY9h81w8xsUFTR4OEPrdQJtt633Dagqg22xLUzzDhT4rrRQ5xDxAAwiYQOu8XHpXH2UEYq2wcV3du-yRcCVc7qUJGT8oLsWdnXrkpRUWV5B19i8KyE7pPyhuPBzTP0J-Xox__LhI-3vbKAmSnhLhYlmgWbKMMORzQTMKIYM0yLNS5CZKhHr3OaxUMkMh1RmZK4iJhMVGo6eehadkuOqruwzAlIHWWBim0cIoS6cxzS-ZuhzRSqXIp-QcFBdavqG5u5ejTIdWzF7DaSogdRrII0n5M34ze7QzuOvs88Gi0j7rd2kKIxDdSn4hLwah1FDLtKiKlt3fo7zpBOOSzw9WNL4uwgduAQhaELeDmbzY_E_y_L836a_IHdn3vJcquIZOW73nX1JbptvaDv7KTlKVmv33CT-Kabk5P18sVxNXe7rcuo31HevjRYV
linkProvider Springer Nature
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQZQL78JCgUGCE1jk5SRGQqiCVq26u6qqUvUWbMeRImWTZZOA-ou48RsZO4-CKnrrgeMqideyP88343kR8kprqXjMJdWMSRq4gUu5kCGNZeYKVOiZsOWaTqbRfB6fnvLDNfJryIUxYZWDTLSCOq2UuSN_h2LUCFMes4_Lb9R0jTLe1aGFRgeLA332A022-sP-Z9zf1563u3P8aY_2XQWo8iPW0Fj5niMDoQLFkG-dQIkAdSCNikiEupOIQ5npLIxF5OEjkSqeCT_gkXAVQ1sy9XHca-Q6ynHXhJBFRyejgYdsaX2jPGA0RGLuk3Rsqp41TigyJEXOQCs-_JsIL2i3FzyzlvB27_xvS3WX3O5Va9juzsI9sqbL--TmrA8eeEB-Hh5tz3YgNxkxla2zrIZud5CXUCMhQWNxCE27qFY1iDKFRb7IVf0eBNhKvFBl4DMHFLJ_DabYc2GuN3AFIW9qHHypVyZCBkwKqwnDQisHZNvAsmpMYJYoijNoa521BaRdmCNOF_6MI3hIvlzJMm2S9bIq9WMCXDqpo0Kd-biJxoUZSPyZop3pi4zH2YS4A2gS1RdxN71EimQsP22BliDQEgu0JJyQN-M3y66EyaVvbw2gSnpxVifniJqQl-Nj3CHjXRKlrlr7jrk9iBgO8ajD8Ph3PhqtEdLuhLwdQH0--L_n8uTyubwgG3vHs2ky3Z8fPCW3PHu4TGjmFllvVq1-Rm6o74ib1XN7TIF8vWqw_wY00Hd3
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgiouvB8LBQYJTmA178RICFW0K6q2qxUC1FuwHUeKtJssmwTUX8R_4Ncxdh4FVfTWA8dVEq9lf56H55sZgBdaS8UTLpkOQ8kCN3AZFzJiicxdQQZ9KGy5pi9H8WyWnJzw-Qb8GnJhDK1ykIlWUGeVMnfkOyRGjTDlSbiT97SI-d703eobMx2kTKR1aKfRQeRQn_4g961-e7BHe_3S86b7n95_YH2HAab8OGxYonzPkYFQgQpJ9zqBEgHZQ5qMkpjsKJFEMtd5lIjYo0ciUzwXfsBj4aqQ_MrMp3GvwNXYFC23tMH56OyR5rRxUh6ELCIl3Sfs2LQ966gw0paM9Ad59NHfSvGcpXsuSmuV3_Tm_7xst-BGb3LjbndGbsOGLu_A1nFPKrgLP-cfd4_3sTCZMpWtv6yGLnhYlFiTosLG4hObdlmtaxRlhstiWaj6DQq0FXqxytEPHVRkFdRoikAvzLUHrSYWTU2Dr_TaMGfQpLYaehZ5PyjbBldVYwhbYrE4xbbWtHyYdfRHmi7-yS-4B58vZZnuw2ZZlfohIJdO5qhI5z5tqAltBpJ-ZuR_-iLnST4BdwBQqvri7qbHyCIdy1Jb0KUEutSCLo0m8Gr8ZtWVNrnw7e0BYGkv5ur0DF0TeD4-ph0yUSdR6qq175hbhTikIR50eB7_zidnNiZ1PIHXA8DPBv_3XB5dPJdnsEUYT48OZoeP4bpnz5lhbG7DZrNu9RO4pr4TbNZP7YlF-HrZWP8N1SGAGQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PRAME+immunohistochemistry+in+soft+tissue+tumors+and+mimics%3A+a+study+of+350+cases+highlighting+its+imperfect+specificity+but+potentially+useful+diagnostic+applications&rft.jtitle=Virchows+Archiv+%3A+an+international+journal+of+pathology&rft.au=Cammareri%2C+Chlo%C3%A9&rft.au=Beltzung%2C+Fanny&rft.au=Michal%2C+Michael&rft.au=Vanhersecke%2C+Lucile&rft.date=2023-08-01&rft.pub=Springer+Berlin+Heidelberg&rft.issn=0945-6317&rft.eissn=1432-2307&rft.volume=483&rft.issue=2&rft.spage=145&rft.epage=156&rft_id=info:doi/10.1007%2Fs00428-023-03606-6&rft.externalDocID=10_1007_s00428_023_03606_6
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0945-6317&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0945-6317&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0945-6317&client=summon